Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclacumab after index vaso-occlusive crisis in sickle cell disease
PACTR202106894720601Phase 3Recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Inclacumab with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1 recurrent vaso-occlusive crisis requiring admission and parenteral pain medication within 90 days. Started Jul 2021; status: recruiting.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202106894720601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106894720601.